Wearable Health Solutions (WHSI) 10-Q 20 Feb 24 2024 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Dec. 31, 2023	Feb. 20, 2024
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2023
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--06-30
Entity File Number	000-56368
Entity Registrant Name	WEARABLE HEALTH SOLUTIONS, INC.
Entity Central Index Key	0001443089
Entity Tax Identification Number	26-3534190
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	10535 N Port Washington Rd.
Entity Address, Address Line Two	Suite 204
Entity Address, City or Town	Mequon
Entity Address, State or Province	WI
Entity Address, Postal Zip Code	53092
City Area Code	877
Local Phone Number	639-2929
Entity Current Reporting Status	Yes
Entity Interactive Data Current	No
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		1,826,705,108

Consolidated Balance Sheets (Un

Consolidated Balance Sheets (Unaudited) - USD ($)	Dec. 31, 2023	Jun. 30, 2023
Current Assets
Cash and cash equivalents	$ 410	$ 136,151
Accounts receivable, net	26,685	379
Inventory	5,120	8,555
Prepaid inventory	0	7,242
Total Current Assets	32,215	152,327
Property and equipment, net	32,115	38,689
Right-of-use assets	25,250	32,157
Total Assets	89,580	223,173
LIABILITIES AND SHAREHOLDERS' DEFICIT
COMMITMENTS AND CONTINGENCIES
Current Liabilities
Accounts payable	176,758	162,936
Accrued expenses and other current liabilities	453,347	517,067
Short-term lease liability	14,856	14,039
Related party debt, net	801,974	799,132
Deferred revenue	157,310	103,412
Line of credit	0	397,500
Notes payable	398,333	398,333
Notes payable - other	50,000	50,000
Notes payable - related party	279,940	170,000
Convertible notes - Leonite	295,122	246,148
Convertible notes - other	518,750	673,750
Stock subscription liability	25,000	249,500
Total Current Liabilities	3,171,390	3,781,817
Long-term lease liability	10,815	18,468
Total Liabilities	3,182,205	3,800,285
SHAREHOLDERS' DEFICIT
Common stock: $0.0001 par value; 3,000,000,000 shares authorized, 1,826,705,108 and 1,566,255,108 shares issued and outstanding as of December 31, 2023 and June 30, 2023, respectively	182,670	156,625
Common stock to be issued 48,725,832 and 169,767,499 shares as of December 31, 2023 and June 30, 2023, respectively	216,189	604,335
Additional paid-in capital	38,175,219	37,472,648
Accumulated deficit	(41,667,716)	(41,811,849)
Total Shareholders' Deficit	(3,092,625)	(3,577,112)
Total Liabilities and Shareholders' Deficit	89,580	223,173
Series A Preferred Stock [Member]
SHAREHOLDERS' DEFICIT
Preferred stock	1	1
Series B Preferred Stock [Member]
SHAREHOLDERS' DEFICIT
Preferred stock	1	1
Series C Preferred Stock [Member]
SHAREHOLDERS' DEFICIT
Preferred stock	568	684
Series D Preferred Stock [Member]
SHAREHOLDERS' DEFICIT
Preferred stock	43	43
Series E Preferred Stock [Member]
SHAREHOLDERS' DEFICIT
Preferred stock	$ 400	$ 400

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Dec. 31, 2023	Jun. 30, 2023
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	3,000,000,000	3,000,000,000
Common stock, shares issued	1,826,705,108	1,566,255,108
Common stock, shares outstanding	1,826,705,108	1,566,255,108
Common stock to be issued	48,725,832	169,767,499
Series A Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	100,000	100,000
Preferred stock, shares issued	688	688
Preferred stock, shares outstanding	688	688
Series B Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	62,500	62,500
Preferred stock, shares issued	9,938	9,938
Preferred stock, shares outstanding	9,938	9,938
Series C Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	6,944,445	6,944,445
Preferred stock, shares issued	5,676,839	6,838,889
Preferred stock, shares outstanding	5,676,839	6,838,889
Series D Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	500,000	500,000
Preferred stock, shares issued	425,000	425,000
Preferred stock, shares outstanding	425,000	425,000
Series E Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	4,000,000	4,000,000
Preferred stock, shares issued	4,000,000	4,000,000
Preferred stock, shares outstanding	4,000,000	4,000,000

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Revenue	$ 127,250	$ 198,039	$ 269,662	$ 414,499
Cost of sales	(83,265)	(99,418)	(133,392)	(219,420)
Gross profit	43,985	98,621	136,270	195,079
Operating expenses
Selling expense	340	80,272	625	270,282
Depreciation	3,287	3,287	6,574	5,831
Research and development expense	0	0	15,200	2,180
Consulting and professional fees	50,750	65,505	175,935	107,819
Insurance	589	27,326	12,725	56,518
Rent	4,080	6,780	8,160	12,190
Salaries and wages	27,784	354,429	215,724	857,285
General and administrative	28,854	80,449	108,757	162,426
Total operating expenses	115,684	618,048	543,700	1,474,531
Loss from operations	(71,699)	(519,427)	(407,430)	(1,279,452)
Other income / (expense), net
Other income	0	0	0	19,500
Interest income	0	0	0	1,500
Gain on debt extinguishment	239,834	0	637,334	0
Interest expense	(42,904)	(20,364)	(85,771)	(30,106)
Total other income (expense), net	196,930	(20,364)	551,563	(9,106)
Net income (loss) before income taxes	125,231	(539,791)	144,133	(1,288,558)
Income taxes	0	0	0	0
Net income (loss)	125,231	(539,791)	144,133	(1,288,558)
Preferred stock extinguishment	65,075	0	65,075	0
Net income (loss) attributable to common holders	$ 190,306	$ (539,791)	$ 209,208	$ (1,288,558)
Net income (loss) per common share - Basic	$ 0	$ 0	$ 0	$ 0
Net income (loss) per common share - Diluted	$ 0	$ 0	$ 0	$ 0
Weighted average common shares outstanding - Basic	1,822,312,717	1,531,592,608	1,726,290,434	1,524,691,793
Weighted average common shares outstanding - Diluted	2,334,578,191	1,531,592,608	2,238,555,908	1,524,691,793

Consolidated Statements of Chan

Consolidated Statements of Changes in Shareholders' Deficit (Unaudited) - USD ($)	Preferred Stock Series A [Member]	Preferred Stock Series B [Member]	Preferred Stock Series C [Member]	Preferred Stock Series D [Member]	Preferred Stock Series E [Member]	Common Stock [Member]	Common Stock To Be Issued [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Jun. 30, 2022	$ 1	$ 1	$ 684	$ 43	$ 400	$ 149,314	$ 407,677	$ 36,773,035	$ (39,423,382)	$ (2,092,227)
Beginning balance, shares at Jun. 30, 2022	688	9,938	6,838,889	425,000	4,000,000	1,493,142,608	35,602,500
Income for the period									(748,767)	(748,767)
Common stock for compensation						$ 500	$ (30,000)	65,500		36,000
Common stock for compensation, shares						5,000,000	(2,000,000)
Common stock to be issued for compensation							$ 441			441
Common stock to be issued for compensation, shares							32,500
Common stock for officer compensation						$ 695	$ (101,262)	100,567
Common stock for officer compensation, shares						6,950,000	(6,950,000)
Common stock to be issued for officer compensation							$ 47,144			47,144
Common stock to be issued for officer compensation, shares							3,475,000
Shares issued for services						$ 500		88,500		89,000
Shares issued for services, shares						5,000,000
Shares sold for cash - prior quarter						$ 2,150	$ (215,000)	212,850
Shares sold for cash - prior quarter, shares						21,500,000	(21,500,000)
Shares sold for cash - current quarter							$ 604,500			604,500
Shares sold for cash - current quarter, shares							67,950,000
Payment of subscription receivable								30,000		30,000
Ending balance, value at Sep. 30, 2022	$ 1	$ 1	$ 684	$ 43	$ 400	$ 153,159	$ 713,500	37,270,452	(40,172,149)	(2,033,909)
Ending balance, shares at Sep. 30, 2022	688	9,938	6,838,889	425,000	4,000,000	1,531,592,608	76,610,000
Beginning balance, value at Jun. 30, 2022	$ 1	$ 1	$ 684	$ 43	$ 400	$ 149,314	$ 407,677	36,773,035	(39,423,382)	(2,092,227)
Beginning balance, shares at Jun. 30, 2022	688	9,938	6,838,889	425,000	4,000,000	1,493,142,608	35,602,500
Income for the period										(1,288,558)
[custom:ReversalOfCommonStockIssuedForOfficerCompensation]
Preferred stock extinguishment										0
Ending balance, value at Dec. 31, 2022	$ 1	$ 1	$ 684	$ 43	$ 400	$ 153,159	$ 811,068	37,270,501	(40,711,940)	(2,476,083)
Ending balance, shares at Dec. 31, 2022	688	9,938	6,838,889	425,000	4,000,000	1,531,592,608	95,430,000
Beginning balance, value at Jun. 30, 2022	$ 1	$ 1	$ 684	$ 43	$ 400	$ 149,314	$ 407,677	36,773,035	(39,423,382)	(2,092,227)
Beginning balance, shares at Jun. 30, 2022	688	9,938	6,838,889	425,000	4,000,000	1,493,142,608	35,602,500
Ending balance, value at Jun. 30, 2023	$ 1	$ 1	$ 684	$ 43	$ 400	$ 156,625	$ 604,335	37,472,648	(41,811,849)	(3,577,112)
Ending balance, shares at Jun. 30, 2023	688	9,938	6,838,889	425,000	4,000,000	1,566,255,108	169,767,499
Beginning balance, value at Sep. 30, 2022	$ 1	$ 1	$ 684	$ 43	$ 400	$ 153,159	$ 713,500	37,270,452	(40,172,149)	(2,033,909)
Beginning balance, shares at Sep. 30, 2022	688	9,938	6,838,889	425,000	4,000,000	1,531,592,608	76,610,000
Income for the period									(539,791)	(539,791)
Common stock to be issued for compensation							$ 210			210
Common stock to be issued for compensation, shares							32,500
Common stock for officer compensation
Common stock to be issued for officer compensation							$ 22,422	49		22,471
Common stock to be issued for officer compensation, shares							3,475,000
Shares issued for services
Commitment shares - Leonite convertible notes							$ 49,936			49,936
Commitment shares - Leonite convertible notes, shares							15,000,000
Shares sold for cash - prior quarter
Shares sold for cash - current quarter							$ 25,000			25,000
Shares sold for cash - current quarter, shares							312,500
[custom:ReversalOfCommonStockIssuedForOfficerCompensation]
Preferred stock extinguishment										0
Ending balance, value at Dec. 31, 2022	$ 1	$ 1	$ 684	$ 43	$ 400	$ 153,159	$ 811,068	37,270,501	(40,711,940)	(2,476,083)
Ending balance, shares at Dec. 31, 2022	688	9,938	6,838,889	425,000	4,000,000	1,531,592,608	95,430,000
Beginning balance, value at Jun. 30, 2023	$ 1	$ 1	$ 684	$ 43	$ 400	$ 156,625	$ 604,335	37,472,648	(41,811,849)	(3,577,112)
Beginning balance, shares at Jun. 30, 2023	688	9,938	6,838,889	425,000	4,000,000	1,566,255,108	169,767,499
Income for the period									18,902	18,902
Common stock for officer compensation							$ 1,954			1,954
Common stock for officer compensation, shares							1,958,333
Shares sold for cash - prior quarter						$ 13,800	$ (405,000)	391,200
Shares sold for cash - prior quarter, shares						138,000,000	(138,000,000)
Shares sold for cash - current quarter						$ 10,000	$ 15,000	89,000		114,000
Shares sold for cash - current quarter, shares						100,000,000	15,000,000
Ending balance, value at Sep. 30, 2023	$ 1	$ 1	$ 684	$ 43	$ 400	$ 180,425	$ 216,289	37,952,848	(41,792,947)	(3,442,256)
Ending balance, shares at Sep. 30, 2023	688	9,938	6,838,889	425,000	4,000,000	1,804,255,108	48,725,832
Beginning balance, value at Jun. 30, 2023	$ 1	$ 1	$ 684	$ 43	$ 400	$ 156,625	$ 604,335	37,472,648	(41,811,849)	(3,577,112)
Beginning balance, shares at Jun. 30, 2023	688	9,938	6,838,889	425,000	4,000,000	1,566,255,108	169,767,499
Income for the period										144,133
[custom:ReversalOfCommonStockIssuedForOfficerCompensation]
Preferred stock extinguishment										65,075
Ending balance, value at Dec. 31, 2023	$ 1	$ 1	$ 568	$ 43	$ 400	$ 182,670	$ 216,189	38,175,219	(41,667,716)	(3,092,625)
Ending balance, shares at Dec. 31, 2023	688	9,938	5,676,839	425,000	4,000,000	1,826,705,108	48,725,832
Beginning balance, value at Sep. 30, 2023	$ 1	$ 1	$ 684	$ 43	$ 400	$ 180,425	$ 216,289	37,952,848	(41,792,947)	(3,442,256)
Beginning balance, shares at Sep. 30, 2023	688	9,938	6,838,889	425,000	4,000,000	1,804,255,108	48,725,832
Income for the period									125,231	125,231
Common stock for officer compensation							$ 460			460
Common stock for officer compensation, shares							600,000
Reversal of common stock issued for former officer compensation							$ 560			560
Shares sold for cash - prior quarter						$ 2,245		222,255		224,500
Shares sold for cash - prior quarter, shares						22,450,000
[custom:ReversalOfCommonStockIssuedForOfficerCompensation]
Reversal of common stock issued for former officer compensation, shares							(600,000)
Cancellation of Preferred C shares			$ (116)					(64,959)		(65,075)
Cancellation of Preferred C shares, shares			(1,162,050)
Preferred stock extinguishment								65,075		65,075
Reversal of common stock issued for former officer compensation							(560)			(560)
Ending balance, value at Dec. 31, 2023	$ 1	$ 1	$ 568	$ 43	$ 400	$ 182,670	$ 216,189	$ 38,175,219	$ (41,667,716)	$ (3,092,625)
Ending balance, shares at Dec. 31, 2023	688	9,938	5,676,839	425,000	4,000,000	1,826,705,108	48,725,832

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Cash flow from operating activities
Net income (loss)	$ 144,133	$ (1,288,558)
Adjustment for non-cash charges and other items:
Depreciation	6,574	5,831
Amortization of deferred debt issuance costs	23,974	3,480
Amortization of debt discount	25,000	3,629
Stock based compensation expense	1,854	195,266
Gain on debt extinguishment	(637,334)	0
Total adjustments	(435,799)	(1,080,352)
Changes in working capital
Decrease / (increase) in accounts receivable	(26,306)	(9,206)
Decrease / (increase) in inventory	3,435	(57,106)
Decrease / (increase) in prepaid inventory	7,242	62,040
Decrease / (increase) in prepaid expenses	0	(3,900)
(Decrease) / increase in accounts payable	13,822	(12,079)
(Decrease) / increase in accrued expenses	6,185	29,883
(Decrease) / increase in accrued expenses - related party	192,572	26,814
(Decrease) / increase in deferred revenue	53,898	(11,874)
Total changes in working capital	250,848	24,572
Cash flow used in operating activities	(184,951)	(1,055,780)
Cash flow used in investing activities
Purchase of property and equipment	0	(9,442)
Cash flow used in investing activities	0	(9,442)
Cash flow provided by financing activities
Proceeds received from related parties	90,210	155,800
Proceeds from issuance of convertible notes	0	240,000
Repayments of note payable	(155,000)	(15,109)
Proceeds from issuance of stock (net of subscriptions receivable) and stock subscription liability	114,000	659,500
Cash flow from financing activities	49,210	1,040,191
Decrease in cash and cash equivalents	(135,741)	(25,031)
Cash and cash equivalents at beginning of the period	136,151	70,505
Cash and cash equivalents at end of the period	410	45,474
Cash paid during the periods for:
Interest	0	0
Taxes	0	0
Supplemental Disclosures of Non-Cash Financing Activities
Note payable issued to related party as reclassification of amounts due	$ 279,940	$ 0

Nature and Continuance of Opera

Nature and Continuance of Operations	6 Months Ended
	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature and Continuance of Operations	Note 1 – Nature and Continuance of Operations Wearable Healthcare Solutions Inc. (the Company) was incorporated as Medical Alarm Concepts Holding, Inc. on June 4, 2008, under the laws of the State of Nevada. The Company was formed for the sole purpose of acquiring all of the membership units of Medical Alarm Concepts LLC, a Pennsylvania limited liability company (“Medical LLC”). On May 26, 2016, the Company filed an Amended and Restated Articles of Incorporation with the Secretary of State of the State of Nevada to change its name from “Medical Alarm Concepts, Inc.” to “Wearable Health Solutions, Inc.” The Company provides mobile health (mHealth) products and services to be used by customers in case of an emergency. As a provider of personal emergency devices, the Company provides innovative wearable healthcare products, tracking services, and turn-key solutions that enable our users to be proactive with their health, as well as safe and protected. The Company’s flagship products are the iHelp devices, the 3G and the next generation iHelp MAX™ – personal emergency alarm that are used to summon help in the event of an emergency at home. Basis of presentation The accompanying interim consolidated financial statements are unaudited, but in the opinion of management of Wearable Healthcare Solutions, Inc. (the Company), contain all adjustments, which include normal recurring adjustments, necessary to present fairly the financial position at December 31, 2023, and the results of operations and changes in shareholders’ deficit for the three and six months ended December 31, 2023 and cash flows for the six months ended December 31, 2023. The balance sheet as of June 30, 2023, is derived from the Company’s audited financial statements. These unaudited condensed consolidated financial statements reflect all adjustments including normal recurring adjustments, which, in the opinion of management, are necessary to present fairly the financial position, results of operations, and cash flows for the periods presented in accordance with accounting principles generally accepted in the United States of America, or GAAP. These unaudited condensed consolidated financial statements and notes included herein should be read in conjunction with the Company’s consolidated financial statements and notes thereto for the years ended June 30, 2023 and 2022, which are included in the Company’s June 30, 2023 Annual Report on Form 10-K filed with the United States Securities and Exchange Commission on October 20, 2023. Certain information and footnote disclosures normally included in financial statements that have been prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission, although management of the Company believes that the disclosures contained in these financial statements are adequate to make the information presented therein not misleading. For further information, refer to the financial statements and the notes thereto included in the Company’s Annual Report on this Form 10-K for the fiscal year ended June 30, 2023. The results of operations for the three and six months ended December 31, 2023, are not necessarily indicative of the results of operations to be expected for the full fiscal year ending June 30, 2024.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 – Summary of Significant Accounting Policies Principles of Consolidation Use of Estimates Cash and Cash Equivalents Accounts Receivable 26,685 379 23,705 23,705 Software Development for internal use Concentration of Credit Risk Recognition of Revenues Recognition of Revenues The Company’s revenues are derived principally from utilizing new technology in the medical alarm industry to provide 24-hour personal response monitoring services and related products to subscribers with medical or age-related conditions. The Company recognizes revenue when it is realized or realizable and earned. For hardware sales, the Company recognizes revenues at a point in time when the product is shipped. Customers are billed on Net 30 terms. For service revenue, the Company recognizes revenues over the term of the service contract and when the services are rendered. For customers who pay several months at a time, the Company records revenues for the month’s services and the balance of funds to deferred revenues and records the balance of revenues as they become current. Schedule of revenues Three Months Ended Six Months Ended Revenue 2023 2022 2023 2022 Hardware revenue $ 11,374 23,849 $ 37,129 $ 50,725 Service Revenue 115,876 174,190 232,533 363,774 Total Revenue $ 127,250 198,039 269,662 $ 414,499 Deferred revenues at December 31, 2023 and June 30, 2023 were $ 157,310 103,412 Deferred Taxes ASC 740, Income Taxes, requires a company to first determine whether it is more likely than not (which is defined as a likelihood of more than fifty percent) that a tax position will be sustained based on its technical merits as of the reporting date, assuming that taxing authorities will examine the position and have full knowledge of all relevant information. A tax position that meets this more-likely-than-not threshold is then measured and recognized at the largest amount of benefit that is greater than fifty percent likely to be realized upon effective settlement with a taxing authority. The Federal and state income tax returns of the Company for 2023, 2022, and 2021 are subject to examination by the Internal Revenue Service and state taxing authorities for three (3) years from the date filed. Fair value of financial instruments Level 1 Level 2 Level 3 From time to time, our financial instruments include cash, accounts payable and accrued expenses, convertible notes, lines of credit, and credit cards. Research and Development 0 15,200 0 2,180 Basic and Diluted Loss per Common Share - Schedule of anti-dilutive shares Three months ended Six months ended December 31, December 31, 2023 2022 2023 2022 Series A convertible preferred stock 1,376 1,376 1,376 1,376 Series B convertible preferred stock 19,876 19,876 19,876 19,876 Series C convertible preferred stock 56,768,390 68,388,890 56,768,390 68,388,890 Series D convertible preferred stock 4,250,000 4,250,000 4,250,000 4,250,000 Series E convertible preferred stock 400,000,000 400,000,000 400,000,000 400,000,000 Common stock to be Issued Leonite Convertible notes 15,000,000 15,000,000 15,000,000 15,000,000 Stock subscription liability 2,500,000 – 2,500,000 – Others 33,725,832 1,516,592,608 33,725,832 1,516,592,608 Total potentially dilutive shares 512,265,474 2,004,252,750 512,265,474 2,004,252,750 Schedule of earnings per share Three months ended December 31, Six months ended December 31, 2023 2022 2023 2022 Numerator: Net income (loss) attributable to common holders $ 190,306 $ (539,791 ) $ 209,208 $ (1,288,558 ) Denominator: Weighted average common shares outstanding - basic 1,822,312,717 1,531,592,608 1,726,290,434 1,524,691,793 Weighted average common shares outstanding - diluted 2,334,578,191 1,531,592,608 2,238,555,908 1,524,691,793 Net income (loss) per share - basic 0.00 (0.00 ) 0.00 (0.00 ) Net income (loss) per share - diluted 0.00 (0.00 ) 0.00 (0.00 ) The Company has recognized income for this quarter, as a result, the basic and diluted share bases will not be presented as the same. For the three and six month periods ended December 31, 2023 and 2022, the Company recognized income of $0.00 and $0.00 and incurred losses of ($0.00) and ($0.00) per basic share, respectively. For the three and six month periods ended December 31, 2023 and 2022, the Company recognized income of $0.00 and $0.00 and incurred losses ($0.00) and ($0.00) per diluted share, respectively. Recent Accounting Pronouncements The Company reviewed all recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the AICPA and the SEC, and they did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

Going Concern

Going Concern	6 Months Ended
	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	Note 3 – Going Concern The accompanying consolidated financial statements for the three and six months ended December 31, 2023 and 2022 have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As at December 31, 2023 and June 30, 2023, the Company has shown losses for the last two years and has an accumulated deficit of ($ 41,667,716 41,811,849 During the six months ended December 31, 2023, the Company has net cash used in operating activities of $ 184,951 1,854 144,133 49,210 3,139,175 Management believes that the Company’s capital requirements will depend on many factors including the success of the Company’s development efforts and its efforts to raise capital. Management also believes the Company needs to raise additional capital for working capital purposes. There can be no assurance that the Company will be able to obtain the additional capital resources necessary to implement its business plan or that any assumptions relating to its business plan will prove accurate. These factors raise substantial doubt about our ability to continue as a going concern for a period of 12 months from the issue date of this report. The consolidated financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

Inventory, Prepaid Inventory, a

Inventory, Prepaid Inventory, and Prepaid Expenses	6 Months Ended
	Dec. 31, 2023
Inventory Disclosure [Abstract]
Inventory, Prepaid Inventory, and Prepaid Expenses	Note 4 – Inventory, Prepaid Inventory, and Prepaid Expenses The Company maintains some inventory in its warehouse and purchases some of its inventory overseas. Inventories, except for stock in transit, are stated at lower of cost and net realizable value. Stock in transit is valued at cost comprising invoice value plus other charges thereon. Net realizable value is the estimated selling price in ordinary course of business less estimated costs of completion and selling expenses. The quantity of inventory may vary from time to time depending on the delivery schedule of overseas shipments. As of December 31, 2023 and June 30, 2023, the Company had $ 5,120 8,555 0 7,242

Property and Equipment

Property and Equipment	6 Months Ended
	Dec. 31, 2023
Property, Plant and Equipment [Abstract]
Property and Equipment	Note 5 – Property and Equipment The Company has $20,000 in furnishings, $19,689 in office computers and equipment, and capitalized software development costs of $45,900 which are fully depreciated. On August 30, 2021, the Company purchased its dealer portal for $50,000 for internal use, amortized over 60 months. On September 26, 2022, the Company purchased used furniture for $ 9,442 36 As of December 31, 2023 and June 30, 2023, the Company recorded $ 32,115 and $ 38,689 in net Property and Equipment, respectively: Schedule of property and equipment December 31, June 30, 2023 2023 Furniture $ 20,000 $ 20,000 Office computers, equipment, software 19,689 19,689 Software development costs 45,900 45,900 Dealer portal 50,000 50,000 Furniture 9,443 9,443 Property, plant, and equipment 145,032 145,032 Less accumulated depreciation (112,917 ) (106,343 ) Net property, plant, and equipment $ 32,115 $ 38,689

Accounts payable and accrued ex

Accounts payable and accrued expenses and liabilities	6 Months Ended
	Dec. 31, 2023
Payables and Accruals [Abstract]
Accounts payable and accrued expenses and liabilities	Note 6 – Accounts payable and accrued expenses and liabilities The Company recorded accounts payable of $ 176,758 162,936 Accrued expenses and other current liabilities are expenses that have been incurred but not yet paid, and mainly include legal fees, audit fees and other professional fees as well as accrued interest in connection with the credit line and notes payable. The Company recorded $ 453,347 517,067

Notes Payable and Note payable-

Notes Payable and Note payable-other	6 Months Ended
	Dec. 31, 2023
Debt Disclosure [Abstract]
Notes Payable and Note payable-other	Note 7 – Notes Payable and Note payable-other Notes payable consists of notes payable from our subsidiary, notes payable-other, convertible notes payable, notes payable for stock purchases under Reg A, short term notes payable, and notes payable-BOAPIN portal, as follows: Schedule of short term notes payable December 31 June 30, 2023 2023 Notes from subsidiary $ 158,333 $ 158,333 Notes payable - Reg A deposits 140,000 140,000 Short term bridge loan 100,000 100,000 Total notes payable $ 398,333 $ 398,333 Notes Payable - subsidiary The Company has various loans and credit lines outstanding. The credit line carries an interest rate of 6.24 9.24 10.90 Schedule of loans and credit lines outstanding December 31 June 30, 2023 2023 Wells Fargo Loan $ 8,770 $ 8,770 On Deck Loan 139,569 139,569 Prosper Loans 9,994 9,994 $ 158,333 $ 158,333 Short term bridge loan - COHEN On July 31, 2020, the Company secured a $ 500,000 12 On August 19, 2021, the Company repaid $ 300,000 100,000 At December 31, 2023 and June 30, 2023, the Company recorded a short term note payable of $ 100,000 3,000 6,000 3,000 6,000 94,677 88,677 Note payable – stock purchases under Reg A At December 31, 2023 and June 30, 2023, the Company has recorded $ 140,000 140,000 2,700 5,400 2,700 5,400 28,507 23,107 Note Payable – Other In November, 2016, the Company secured a $ 50,000 4 During the three and six months ended December 31, 2023, the Company recorded interest expense of $ 500 1,000 500 1,000 14,282 13,282 Convertible note payable – BENZA, D2CF On March 1, 2016 and March 3, 2016, the Company closed a private placement of debt and received an aggregate of $ 612,500 13,750 660,000 On July 21, 2023, the Company entered into settlement agreements with the principals of the company. In the Nevada Lawsuit (see Note 10), the Company agreed to settle for $345,000, with $145,000 paid upon signing and $200,000 due within 6 months. The Settlement Agreement allows for an increased payment of $600,000 if the Second Nevada Settlement Payment isn’t made within six months. In the New York Lawsuit (see Note 10), the Company will pay $80,000, with $10,000 due upon execution of the Settlement. Payments received by the Company will be applied first to the Second New York Payment. On July 26, 2023 the company paid $ 145,000 10,000 On February 6, 2024, the Company entered into an amendment to Settlement Agreement related to above two litigations where within two days of the signing of this Amendment, WHSI shall make total payments in the amount of twenty thousand dollars ($20,000) and a ten thousand payment ($10,000) made on or before April 5th, 2024, to “GRQ” pursuant to the payment instructions provided by Mr. Honig. This $20,000 payment shall be credited to the Second Nevada Settlement Payment for the Benza Pharma LLC note as that term is defined in the Settlement Agreement. All outstanding principal and accrued interest shall be due on April 15th, 2024 (the “Extended Due Date”). As of December 31, 2023 and June 30, 2023, the Company reported $ 518,750 673,750 Convertible Note – Leonite Capital, LLC On December 5, 2022, the Company received $ 250,000 62,500 March 5, 2024 8,789 17,578 related to the convertible notes. As of December 31, 2023 and June 30, 2023, the Company reported $ 295,122 246,148 The Company will begin making nine equal amortization payments of $ 34,722 15,000,000 commitment shares valued at $ 78,000 28,064 10,000 59,936 11,987 12,500 The Leonite Convertible Note bears annual interest at the greater of 10% or the Prime Rate plus three percent (3%). Credit line – MediPendant New York Inc. On September 30, 2014, the subsidiary received a line of credit with Medi Pendant New York, Inc. (“MNY). Under the original terms of the line of credit agreement, the Company was able to borrow up to $ 300,000 6.5 September 30, 2017 500,000 200,000 25,653 8,436 397,500 As of December 31, 2023 and June 30, 2023, the balance due on the line of credit was $ 0 397,500 Debt settlement – On Deck, Susquehanna, MCA Cure In 2019, our subsidiary engaged MCA CURE to negotiate settlements with two creditors: On Deck and Susquehanna Salt, noted in the table above. The Company ceased paying the loan payments and paid to MCA Cure $43,875 in 2019 and $47,000 in 2020, at which point the Company was contacted and MCA Cure assured they had enough funds to negotiate with the creditors. In 2020, the Company discovered MCA Cure had not performed when bank accounts were levied for $33,705 by the creditors. $18,705 was subsequently refunded by the collection firm. On September 30, 2020, the bank accounts were again levied for additional funds. Currently the Company has a settlement agreement in place with Susquehanna Salt Loan, and has booked a reserve against the $90,875 funds paid to MCA Cure. The Company has hired an attorney and is making every effort to recover funds and damages from MCA Cure. To date, there has been no resolution to the situation. As of December 31, 2023 and June 30, 2023, the Company recorded $ 0 0 139,569 139,569 0 0

Shareholders_ Deficit

Shareholders’ Deficit	6 Months Ended
	Dec. 31, 2023
Equity [Abstract]
Shareholders’ Deficit	Note 10 – Shareholders’ Deficit Preferred Stock: The Company is currently authorized to issue 25,000,000 0.0001 Series A Convertible Preferred Stock 0.0001 Series B Convertible Preferred Stock 0.0001 Series C Convertible Preferred Stock 0.0001 The Company issued 6,700,003 On November 28, 2023, 1,162,050 65,075 As of December 31, 2023 and June 30, 2023, 5,676,839 6,838,889 Series D Convertible Preferred Stock : 0.0001 425,000 Series E Convertible Preferred Stock : 0.0001 As of December 31, 2023 and June 30, 2023, 4,000,000 Common Stock The Company is currently authorized to issue 3,000,000,000 0.0001 During the six months ended December 31, 2023, · the Company has issued 100,000,000 99,000 · the Company issued 160,450,000 During the six months ended December 31, 2023, the Company also recorded shares to be issued of 1,958,333 1,854 During the six months ended December 31, 2023, the Company received proceeds totaling $114,000 in connection with the issuance of 115,000,000 shares of common stock. Of the total proceeds received, $99,000 in proceeds was received from the issuance of 100,000,000 common shares that were issued under the terms of subscription agreements at the contract price of $0.0001. Proceeds of $15,000 were received from the issuance of 15,000,000 common shares that were issued under the terms of subscription agreements at the contract price of $0.0001 per share. Of these issuances, only 15,000,000 shares are yet to be issued as of December 31, 2023. As of December 31, 2023 and June 30, 2023, the Company has 1,826,705,108 1,566,255,108

Related Party Transactions

Related Party Transactions	6 Months Ended
	Dec. 31, 2023
Related Party Transactions [Abstract]
Related Party Transactions	Note 11 – Related Party Transactions Note payable – BOAPIN purchase In August 2020, and effective as of June 30, 2020, the Company purchased the BOAPIN portal, including all software, licensing, and ownership rights from Hypersoft Ventures, Inc., a related party through common ownership, for $ 800,200 6,700,003 375,200 425,000 On November 28, 2023, Hypersoft Venture forgave any and all outstanding debt owed by the Company, including $ 170,000 69,834 239,834 As of December 31, 2023 and June 30, 2023, the Company has recorded a note payable of $ 0 170,000 During the three and six months ended December 31, 2023, the Company recorded interest expense of $ 0 0 3,428 6,856 0 63,015 Note payable – Chief Executive Officer On November 3, 2023, the Company entered into a Promissory Note Agreement (the “Promissory Note”) with its Chief Executive Officer Peter Pizzino (“Noteholder”), pursuant to which the Company issued to the Noteholder a Secured Note in an aggregate principal amount of $ 279,940 279,940 The Note accrues interest at the rate of 3 October 7, 2024 g additional indebtedness and dividends. The Company may only prepay the Note with the prior written consent of the respective Noteholder thereof. As of December 31, 2023 and June 30, 2023, the Company has recorded a note payable of $ 279,940 0 Related party debt, net From time to time, the Company received funds from related parties for day-to-day operations. These are short-term loans which bear no interest, and the Company expects to repay these loans by the end of the fiscal year following the year in which the short-term loan was made. The following table reflects the composition of the related party debt, net balance at December 31, 2023 and June 30, 2023. Schedule of related party transactions December 31, June 30, 2023 2023 Related parties – subsidiary $ 177,320 $ 177,320 Accrued salaries, bonus, fees 624,654 621,812 Total loans from related parties, net $ 801,974 $ 799,132

Commitments and contingencies

Commitments and contingencies	6 Months Ended
	Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and contingencies	Note 12 – Commitments and contingencies Legal Matters From time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. 1) Legal Proceedings Involving Aqualaro Corp On October 24, 2022, Aqualaro Corp. filed a lawsuit against the Company and its transfer agent in the Supreme Court of the State of New York, County of New York. Aqualaro sought monetary damages and an injunction to transfer 56 million shares of common stock to an individual. An amended complaint was filed on October 26, 2022. On December 5, 2022, the Company moved to dismiss the amended complaint. On April 13, 2023, the Court granted the Company’s motion but allowed the plaintiff to refile. On April 26, 2023, a second amended complaint was filed against the Company, adding Mr. Pizzino as a defendant. On May 8, 2023, Acqualaro filed a notice of appeal regarding the decision to dismiss the first amended complaint. On August 3, 2023, Aqualaro filed a third amended complaint. On August 14, 2023, the Company moved to dismiss the Third Amended Complaint. 2) Settlement Agreements on July 21, 2023 The Company entered into a Settlement Agreement related to two litigations: – Benza Pharma, LLC, et al. v. Wearable Health Solutions, Inc., et al. in Clark County Nevada. – GRQ Consultants, Inc. v. Wearable Health Solutions Inc. in the Supreme Court of the State of New York. In the Nevada Lawsuit, the Company agreed to settle for $ 345,000 145,000 200,000 In the New York Lawsuit, the Company will pay $ 80,000 10,000 On February 6, 2024, the Company entered into an amendment to Settlement Agreement related to above two litigations where Within two days of the signing of this Amendment WHSI shall make total payments in the amount of twenty thousand dollars ($20,000) and a ten thousand payment ($10,000) made on or before April 5th, 2024, to “GRQ” pursuant to the payment instructions provided by Mr. Honig. This $20,000 payment shall be credited to the Second Nevada Settlement Payment for the Benza Pharma LLC note as that term is defined in the Settlement Agreement. All outstanding principal and accrued interest shall be due on April 15th, 2024 (the "Extended Due Date"). 3) Medical Alarm Concepts LLC v. MCA Cure, LLC The Company sought the return of payments for non-performance, attorney fees, and court costs. An initial settlement was reached where MCA Cure would pay $10,000 upfront and $6,500 monthly until the debt was paid off in 2023. The defendants breached the settlement agreement, leading to a reopened case. A judgment of $ 148,875 4) On October 4, 2023, Mr. Miceli filed a breach of contact complaint in the state of Connecticut against the Company. Other than the aforementioned, we are not presently a party to any legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors. Commitments and Contingencies. If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s financial statements. If the assessment indicates that a potentially material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed. Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed. Management does not believe, based upon information available at this time that these matters will have a material adverse effect on the Company’s financial position, results of operations or cash flows. However, there is no assurance that such matters will not materially and adversely affect the Company’s business, financial position, and results of operations or cash flows.

Office_Warehouse lease

Office/Warehouse lease	6 Months Ended
	Dec. 31, 2023
Officewarehouse Lease
Office/Warehouse lease	Note 13 – Office/Warehouse lease In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which supersedes the current accounting for leases and while retaining two distinct types of leases, finance and operating, (1) requires lessees to record a right of use asset and a related liability for the rights and obligations associated with a lease, regardless of lease classification, and recognize lease expense in a manner similar to current accounting, (2) eliminates most real estate specific lease provisions, and (3) aligns many of the underlying lessor model principles with those in the new revenue standard. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases today. For public companies, the new standard is effective for annual and interim periods in fiscal years beginning after December 15, 2018. For all other entities, including emerging growth companies, this standard is effective for annual reporting periods beginning after December 15, 2019, and interim periods within fiscal years beginning after December 2020. The Company maintains its corporate office at 2901 W. Coast Highway, Suite 200, Newport Beach, CA 92663. The Company currently pays $175 a month for its office space and the term is month-to-month . The Company entered into a new three-year lease agreement on September 9, 2022 for new warehouse space located in Mequon, Wisconsin. The monthly rent for this new warehouse space is currently $1,325 per month for the first twelve months of the lease agreement. Expenditures for the six months ending December 31, 2023 and 2022 are as follows: Schedule of lease cost Six Months Ended 2023 2022 Rent Expenses $ 8,160 $ 12,190 The Company leased a fulfilment center in the U.S., which was classified as an operating lease which subsequently expired on September 30, 2022. The Company determines if an arrangement qualifies as a lease at the lease inception. Operating lease liabilities are recorded based on the present value of the future lease payments over the lease term, assessed as of the commencement date. The Company’s real estate leases, which are for a fulfilment center, generally have a lease term between 3 5 The Company’s lease agreements generally do not specify an implicit borrowing rate, and as such, the Company utilizes its incremental borrowing rate by lease term, in order to calculate the present value of the future lease payments. The discount rate represents a risk-adjusted rate on a secured basis, and is the rate at which the Company would borrow funds to satisfy the scheduled lease liability payment streams commensurate with the lease term. The Company entered into a new three-year lease agreement on September 9, 2022 for new warehouse space located in Mequon, Wisconsin. The monthly rent which commenced in September 2022 is $1,325 per month and increases approximately 3% annually thereafter. The discount rate used was determined based on the available data as of the lease commencement date. The Right-of-use (“ROU”) asset value added as a result of this new lease agreement was $ 43,058 Certain of the Company’s lease agreements, primarily related to real estate, include options for the Company to either renew (extend) or early terminate the lease. Leases with renewal options allow the Company to extend the lease term typically between 1 and 3 years. Renewal options are reviewed at lease commencement to determine if such options are reasonably certain of being exercised, which could impact the lease term. When determining if a renewal option is reasonably certain of being exercised, the Company considers several factors, including but not limited to, significance of leasehold improvements incurred on the property, whether the asset is difficult to replace, or specific characteristics unique to the particular lease that would make it reasonably certain that the Company would exercise such option. In most cases, the Company has concluded that renewal and early termination options are not reasonably certain of being exercised by the Company (and thus not included in the Company’s ROU asset and lease liability) unless there is an economic, financial or business reason to do so. The following summarizes (i) the future minimum undiscounted lease payments under non-cancellable lease for each of the next four years and thereafter, incorporating the practical expedient to account for lease and non-lease components as a single lease component for our existing real estate leases, (ii) a reconciliation of the undiscounted lease payments to the present value of the lease liabilities recognized, and (iii) the lease-related account balances on the Company’s consolidated balance sheet, as of December 31, 2023: Schedule of future lease payments Fiscal Year Ending June 30, 2024 $ 8,160 2025 16,670 July & August 2025 2,790 Total future minimum lease payments 27,620 Less imputed interest (1,949 ) Total present value of future minimum lease payments $ 25,671 Schedule of balance sheet related leases As of December 31, 2023 Operating lease right-of-use assets $ 25,250 Accrued lease liability 14,856 Long-term lease liability 10,815 $ 25,671 As of December 31, 2023 Weighted Average Remaining Lease Term 1.67 Weighted Average Discount Rate 8.44

Other income - settlement

Other income - settlement	6 Months Ended
	Dec. 31, 2023
Other Income and Expenses [Abstract]
Other income - settlement	Note 14 – Other income - settlement Settlement In 2019, the Company engaged MCA Cure to negotiate settlements with two note holders, and paid MCA Cure a total of $97,625. In 2020, the Company discovered MCA Cure had not performed when bank accounts were levied for $33,705 and $18,705, being subsequently refunded, and engaged an attorney to recover funds. Currently the Company has a settlement agreement in place with Susquehanna Salt Loan and has hired an attorney to recover funds and damages from MCA Cure. In February 2022, a settlement was reached with MCA Cure for fees and attorney costs of $ 105,125 For the three and six months ended December 31, 2023 and 2022, the Company recorded $ 0 0 0 19,500

Subsequent Events

Subsequent Events	6 Months Ended
	Dec. 31, 2023
Subsequent Events [Abstract]
Subsequent Events	Note 15 – Subsequent Events On January 16, 2024, the Company cancelled 1,250,000 shares of Series C Preferred Stock and 15,000,000 shares of common stock for no consideration. On February 6, 2024, the Company entered into an amendment to the Benza Settlement Agreement (see Note 12). Within two days of the signing of this Amendment, the Company shall make total payments in the amount of $20,000 and a $10,000 payment made on or before April 5, 2024, to “GRQ. This $20,000 payment shall be credited to the Second Nevada Settlement Payment for the Benza Pharma LLC note as that term is defined in the Settlement Agreement. All outstanding principal and accrued interest shall be due on April 15, 2024 (the “Extended Due Date”). The Company evaluated events that have occurred after the balance sheet date but before the financial statements are issued and determined that there are no additional material events that are required to be disclosed.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation
Use of Estimates	Use of Estimates
Cash and Cash Equivalents	Cash and Cash Equivalents
Accounts Receivable	Accounts Receivable 26,685 379 23,705 23,705
Software Development for internal use	Software Development for internal use
Concentration of Credit Risk	Concentration of Credit Risk
Recognition of Revenues	Recognition of Revenues Recognition of Revenues The Company’s revenues are derived principally from utilizing new technology in the medical alarm industry to provide 24-hour personal response monitoring services and related products to subscribers with medical or age-related conditions. The Company recognizes revenue when it is realized or realizable and earned. For hardware sales, the Company recognizes revenues at a point in time when the product is shipped. Customers are billed on Net 30 terms. For service revenue, the Company recognizes revenues over the term of the service contract and when the services are rendered. For customers who pay several months at a time, the Company records revenues for the month’s services and the balance of funds to deferred revenues and records the balance of revenues as they become current. Schedule of revenues Three Months Ended Six Months Ended Revenue 2023 2022 2023 2022 Hardware revenue $ 11,374 23,849 $ 37,129 $ 50,725 Service Revenue 115,876 174,190 232,533 363,774 Total Revenue $ 127,250 198,039 269,662 $ 414,499 Deferred revenues at December 31, 2023 and June 30, 2023 were $ 157,310 103,412
Deferred Taxes	Deferred Taxes ASC 740, Income Taxes, requires a company to first determine whether it is more likely than not (which is defined as a likelihood of more than fifty percent) that a tax position will be sustained based on its technical merits as of the reporting date, assuming that taxing authorities will examine the position and have full knowledge of all relevant information. A tax position that meets this more-likely-than-not threshold is then measured and recognized at the largest amount of benefit that is greater than fifty percent likely to be realized upon effective settlement with a taxing authority. The Federal and state income tax returns of the Company for 2023, 2022, and 2021 are subject to examination by the Internal Revenue Service and state taxing authorities for three (3) years from the date filed.
Fair value of financial instruments	Fair value of financial instruments Level 1 Level 2 Level 3 From time to time, our financial instruments include cash, accounts payable and accrued expenses, convertible notes, lines of credit, and credit cards.
Research and Development	Research and Development 0 15,200 0 2,180
Basic and Diluted Loss per Common Share	Basic and Diluted Loss per Common Share - Schedule of anti-dilutive shares Three months ended Six months ended December 31, December 31, 2023 2022 2023 2022 Series A convertible preferred stock 1,376 1,376 1,376 1,376 Series B convertible preferred stock 19,876 19,876 19,876 19,876 Series C convertible preferred stock 56,768,390 68,388,890 56,768,390 68,388,890 Series D convertible preferred stock 4,250,000 4,250,000 4,250,000 4,250,000 Series E convertible preferred stock 400,000,000 400,000,000 400,000,000 400,000,000 Common stock to be Issued Leonite Convertible notes 15,000,000 15,000,000 15,000,000 15,000,000 Stock subscription liability 2,500,000 – 2,500,000 – Others 33,725,832 1,516,592,608 33,725,832 1,516,592,608 Total potentially dilutive shares 512,265,474 2,004,252,750 512,265,474 2,004,252,750 Schedule of earnings per share Three months ended December 31, Six months ended December 31, 2023 2022 2023 2022 Numerator: Net income (loss) attributable to common holders $ 190,306 $ (539,791 ) $ 209,208 $ (1,288,558 ) Denominator: Weighted average common shares outstanding - basic 1,822,312,717 1,531,592,608 1,726,290,434 1,524,691,793 Weighted average common shares outstanding - diluted 2,334,578,191 1,531,592,608 2,238,555,908 1,524,691,793 Net income (loss) per share - basic 0.00 (0.00 ) 0.00 (0.00 ) Net income (loss) per share - diluted 0.00 (0.00 ) 0.00 (0.00 ) The Company has recognized income for this quarter, as a result, the basic and diluted share bases will not be presented as the same. For the three and six month periods ended December 31, 2023 and 2022, the Company recognized income of $0.00 and $0.00 and incurred losses of ($0.00) and ($0.00) per basic share, respectively. For the three and six month periods ended December 31, 2023 and 2022, the Company recognized income of $0.00 and $0.00 and incurred losses ($0.00) and ($0.00) per diluted share, respectively.
Recent Accounting Pronouncements	Recent Accounting Pronouncements The Company reviewed all recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the AICPA and the SEC, and they did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Schedule of revenues	Schedule of revenues Three Months Ended Six Months Ended Revenue 2023 2022 2023 2022 Hardware revenue $ 11,374 23,849 $ 37,129 $ 50,725 Service Revenue 115,876 174,190 232,533 363,774 Total Revenue $ 127,250 198,039 269,662 $ 414,499
Schedule of anti-dilutive shares	Schedule of anti-dilutive shares Three months ended Six months ended December 31, December 31, 2023 2022 2023 2022 Series A convertible preferred stock 1,376 1,376 1,376 1,376 Series B convertible preferred stock 19,876 19,876 19,876 19,876 Series C convertible preferred stock 56,768,390 68,388,890 56,768,390 68,388,890 Series D convertible preferred stock 4,250,000 4,250,000 4,250,000 4,250,000 Series E convertible preferred stock 400,000,000 400,000,000 400,000,000 400,000,000 Common stock to be Issued Leonite Convertible notes 15,000,000 15,000,000 15,000,000 15,000,000 Stock subscription liability 2,500,000 – 2,500,000 – Others 33,725,832 1,516,592,608 33,725,832 1,516,592,608 Total potentially dilutive shares 512,265,474 2,004,252,750 512,265,474 2,004,252,750
Schedule of earnings per share	Schedule of earnings per share Three months ended December 31, Six months ended December 31, 2023 2022 2023 2022 Numerator: Net income (loss) attributable to common holders $ 190,306 $ (539,791 ) $ 209,208 $ (1,288,558 ) Denominator: Weighted average common shares outstanding - basic 1,822,312,717 1,531,592,608 1,726,290,434 1,524,691,793 Weighted average common shares outstanding - diluted 2,334,578,191 1,531,592,608 2,238,555,908 1,524,691,793 Net income (loss) per share - basic 0.00 (0.00 ) 0.00 (0.00 ) Net income (loss) per share - diluted 0.00 (0.00 ) 0.00 (0.00 )

Property and Equipment (Tables)

Property and Equipment (Tables)	6 Months Ended
	Dec. 31, 2023
Property, Plant and Equipment [Abstract]
Schedule of property and equipment	Schedule of property and equipment December 31, June 30, 2023 2023 Furniture $ 20,000 $ 20,000 Office computers, equipment, software 19,689 19,689 Software development costs 45,900 45,900 Dealer portal 50,000 50,000 Furniture 9,443 9,443 Property, plant, and equipment 145,032 145,032 Less accumulated depreciation (112,917 ) (106,343 ) Net property, plant, and equipment $ 32,115 $ 38,689

Notes Payable and Note payabl_2

Notes Payable and Note payable-other (Tables)	6 Months Ended
	Dec. 31, 2023
Debt Disclosure [Abstract]
Schedule of short term notes payable	Schedule of short term notes payable December 31 June 30, 2023 2023 Notes from subsidiary $ 158,333 $ 158,333 Notes payable - Reg A deposits 140,000 140,000 Short term bridge loan 100,000 100,000 Total notes payable $ 398,333 $ 398,333
Schedule of loans and credit lines outstanding	Schedule of loans and credit lines outstanding December 31 June 30, 2023 2023 Wells Fargo Loan $ 8,770 $ 8,770 On Deck Loan 139,569 139,569 Prosper Loans 9,994 9,994 $ 158,333 $ 158,333

Related Party Transactions (Tab

Related Party Transactions (Tables)	6 Months Ended
	Dec. 31, 2023
Related Party Transactions [Abstract]
Schedule of related party transactions	Schedule of related party transactions December 31, June 30, 2023 2023 Related parties – subsidiary $ 177,320 $ 177,320 Accrued salaries, bonus, fees 624,654 621,812 Total loans from related parties, net $ 801,974 $ 799,132

Office_Warehouse lease (Tables)

Office/Warehouse lease (Tables)	6 Months Ended
	Dec. 31, 2023
Officewarehouse Lease
Schedule of lease cost	Schedule of lease cost Six Months Ended 2023 2022 Rent Expenses $ 8,160 $ 12,190
Schedule of future lease payments	Schedule of future lease payments Fiscal Year Ending June 30, 2024 $ 8,160 2025 16,670 July & August 2025 2,790 Total future minimum lease payments 27,620 Less imputed interest (1,949 ) Total present value of future minimum lease payments $ 25,671
Schedule of balance sheet related leases	Schedule of balance sheet related leases As of December 31, 2023 Operating lease right-of-use assets $ 25,250 Accrued lease liability 14,856 Long-term lease liability 10,815 $ 25,671 As of December 31, 2023 Weighted Average Remaining Lease Term 1.67 Weighted Average Discount Rate 8.44

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details - Schedule of Revenues) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Product Information [Line Items]
Revenues	$ 127,250	$ 198,039	$ 269,662	$ 414,499
Hardware Revenue [Member]
Product Information [Line Items]
Revenues	11,374	23,849	37,129	50,725
Service Revenue [Member]
Product Information [Line Items]
Revenues	$ 115,876	$ 174,190	$ 232,533	$ 363,774

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Details - Antidilutive information) - shares	3 Months Ended		6 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
AntiDilutive Shares	512,265,474	2,004,252,750	512,265,474	2,004,252,750
Series A Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
AntiDilutive Shares	1,376	1,376	1,376	1,376
Series B Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
AntiDilutive Shares	19,876	19,876	19,876	19,876
Series C Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
AntiDilutive Shares	56,768,390	68,388,890	56,768,390	68,388,890
Series D Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
AntiDilutive Shares	4,250,000	4,250,000	4,250,000	4,250,000
Series E Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
AntiDilutive Shares	400,000,000	400,000,000	400,000,000	400,000,000
Leonite Convertible Notes [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
AntiDilutive Shares	15,000,000	15,000,000	15,000,000	15,000,000
Stock Subscription Liability [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
AntiDilutive Shares	2,500,000	0	2,500,000	0
Others [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
AntiDilutive Shares	33,725,832	1,516,592,608	33,725,832	1,516,592,608

Summary of Significant Accoun_6

Summary of Significant Accounting Policies (Details - Reconciliation of earnings per share) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Numerator:
Net income (loss) attributable to common holders	$ 190,306	$ (539,791)	$ 209,208	$ (1,288,558)
Denominator:
Weighted average common shares outstanding - basic	1,822,312,717	1,531,592,608	1,726,290,434	1,524,691,793
Weighted average common shares outstanding - diluted	2,334,578,191	1,531,592,608	2,238,555,908	1,524,691,793
Net income (loss) per share - basic	$ 0	$ 0	$ 0	$ 0
Net income (loss) per share - diluted	$ 0	$ 0	$ 0	$ 0

Summary of Significant Accoun_7

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022	Jun. 30, 2023
Accounting Policies [Abstract]
Accounts receivable, net	$ 26,685		$ 26,685		$ 379
Allowance for doubtful accounts	23,705		23,705		23,705
Deferred revenue	157,310		157,310		$ 103,412
Research and development expense	$ 0	$ 0	$ 15,200	$ 2,180

Going Concern (Details Narrativ

Going Concern (Details Narrative) - USD ($)	3 Months Ended				6 Months Ended
	Dec. 31, 2023	Sep. 30, 2023	Dec. 31, 2022	Sep. 30, 2022	Dec. 31, 2023	Dec. 31, 2022	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit	$ 41,667,716				$ 41,667,716		$ 41,811,849
Net cash used in operating activities					184,951	$ 1,055,780
Stock compensation non-cash expense					1,854	195,266
Net loss	125,231	$ 18,902	$ (539,791)	$ (748,767)	144,133	(1,288,558)
Net cash used in financing activities					49,210	$ 1,040,191
Working capital deficit	$ 3,139,175				$ 3,139,175

Inventory, Prepaid Inventory,_2

Inventory, Prepaid Inventory, and Prepaid Expenses (Details Narrative) - USD ($)	Dec. 31, 2023	Jun. 30, 2023
Inventory Disclosure [Abstract]
Inventory, net	$ 5,120	$ 8,555
Prepaid inventories	$ 0	$ 7,242

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	Dec. 31, 2023	Jun. 30, 2023
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 145,032	$ 145,032
Less accumulated depreciation	(112,917)	(106,343)
Net property, plant, and equipment	32,115	38,689
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	20,000	20,000
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	19,689	19,689
Software Development [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	45,900	45,900
Dealer Portal [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	50,000	50,000
Office Furniture [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 9,443	$ 9,443

Property and Equipment (Detai_2

Property and Equipment (Details Narrative) - USD ($)	Sep. 26, 2022	Dec. 31, 2023	Jun. 30, 2023
Property, Plant and Equipment, Net		$ 32,115	$ 38,689
Used Furniture [Member]
Cost of used furniture	$ 9,442
Useful life of property			36 months

Accounts payable and accrued _2

Accounts payable and accrued expenses and liabilities (Details Narrative) - USD ($)	Dec. 31, 2023	Jun. 30, 2023
Payables and Accruals [Abstract]
Accounts payable	$ 176,758	$ 162,936
Accrued expenses and other current liabilities	$ 453,347	$ 517,067

Notes Payable and Note payabl_3

Notes Payable and Note payable-other (Details - Short term notes) - USD ($)	Dec. 31, 2023	Jun. 30, 2023
Debt Instrument [Line Items]
Notes payable	$ 398,333	$ 398,333
Notes From Subsidiary [Member]
Debt Instrument [Line Items]
Notes payable	158,333	158,333
Notes Payable Reg A Deposits [Member]
Debt Instrument [Line Items]
Notes payable	140,000	140,000
Short Term Bridge Loan [Member]
Debt Instrument [Line Items]
Notes payable	$ 100,000	$ 100,000

Notes Payable and Note payabl_4

Notes Payable and Note payable-other (Details - Notes payable) - USD ($)	Dec. 31, 2023	Jun. 30, 2023
Debt Instrument [Line Items]
Notes payable	$ 158,333	$ 158,333
Wells Fargo Loan [Member]
Debt Instrument [Line Items]
Notes payable	8,770	8,770
On Deck Loan [Member]
Debt Instrument [Line Items]
Notes payable	139,569	139,569
Prosper Loans [Member]
Debt Instrument [Line Items]
Notes payable	$ 9,994	$ 9,994

Notes Payable and Note payabl_5

Notes Payable and Note payable-other (Details Narrative) - USD ($)					1 Months Ended			3 Months Ended					6 Months Ended
	Jul. 26, 2023	Dec. 05, 2022	Jan. 31, 2015	Sep. 30, 2014	Feb. 06, 2024	Nov. 30, 2021	Jul. 31, 2020	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Dec. 31, 2022	Sep. 30, 2022	Dec. 31, 2023	Dec. 31, 2022	Aug. 19, 2021	Nov. 30, 2016	Jun. 30, 2016	Mar. 03, 2016	Mar. 01, 2016	Jun. 30, 2015
Debt Instrument [Line Items]
Credit line interest rate													6.24%
Principle amount repaid															$ 300,000
Repayment of debt						$ 100,000
Short term notes payable								$ 100,000		$ 100,000			$ 100,000
Interest and accrued interest liability								3,000			$ 3,000		6,000	$ 6,000
Accrued interest payable								94,677		88,677			94,677
Notes payable - other								50,000		50,000			50,000
Settlement agreement terms					On February 6, 2024, the Company entered into an amendment to Settlement Agreement related to above two litigations where within two days of the signing of this Amendment, WHSI shall make total payments in the amount of twenty thousand dollars ($20,000) and a ten thousand payment ($10,000) made on or before April 5th, 2024, to “GRQ” pursuant to the payment instructions provided by Mr. Honig. This $20,000 payment shall be credited to the Second Nevada Settlement Payment for the Benza Pharma LLC note as that term is defined in the Settlement Agreement. All outstanding principal and accrued interest shall be due on April 15th, 2024 (the “Extended Due Date”).
Convertible notes balance outstanding								518,750		673,750			518,750
Proceeds from convertible debt													0	240,000
Convertible notes payable - Leonite								295,122		246,148			295,122
Stock issued new, value									$ 114,000		25,000	$ 604,500
Common stock to be issued, value								216,189		604,335			216,189
Amortization of debt issuance costs													23,974	3,480
Amortization of original issue discount													25,000	3,629
Gain on debt extinguishment								239,834			0		637,334	0
Line of credit, outstanding								0		397,500			0
Medi Pendant [Member]
Debt Instrument [Line Items]
Credit line interest rate			6.50%
Accrued Interest																	$ 25,653			$ 8,436
Line of credit borrowing capacity				$ 300,000
Maturity date				Sep. 30, 2017
Line of credit current borrowing capacity			$ 500,000
Stock issued for services, shares			200,000
Gain on debt extinguishment													397,500
Line of credit, outstanding								0		397,500			0
BENZA and D2CF [Member]
Debt Instrument [Line Items]
Debt face amount																			$ 612,500
Convertible notes balance outstanding								518,750		673,750			518,750
B2CF [Member]
Debt Instrument [Line Items]
Convertible notes																			$ 13,750
BENZA [Member]
Debt Instrument [Line Items]
Convertible notes																		$ 660,000
Repayment of convertible notes	$ 145,000
GQR Consultant [Member]
Debt Instrument [Line Items]
Repayment of convertible notes	$ 10,000
Leonite Convertible Note [Member]
Debt Instrument [Line Items]
Interest expense								8,789					17,578
Proceeds from convertible debt		$ 250,000
Original issue discount		$ 62,500
Maturity date		Mar. 05, 2024
Periodic payment													34,722
Legal fees													10,000
Debt issuance costs								59,936					$ 59,936
Amortization of debt issuance costs								11,987
Amortization of original issue discount								12,500
Debt interest rate terms													The Leonite Convertible Note bears annual interest at the greater of 10% or the Prime Rate plus three percent (3%).
Leonite Convertible Note [Member] | Commitment Shares [Member]
Debt Instrument [Line Items]
Stock issued new, shares													15,000,000
Stock issued new, value													$ 78,000
Common stock to be issued, value								28,064					28,064
Leonite Payable [Member]
Debt Instrument [Line Items]
Convertible notes payable - Leonite								295,122		246,148			295,122
Susquehanna [Member]
Debt Instrument [Line Items]
Notes and Loans Payable								0		0			0
Party Related To A Previous C E O [Member]
Debt Instrument [Line Items]
Accrued Interest								14,282		13,282			14,282
Notes payable - other																$ 50,000
Debt stated interest rate																4%
Interest expense								500			500		1,000	1,000
MCA Cure [Member]
Debt Instrument [Line Items]
Prepaid fund								0		0			0
On Deck [Member]
Debt Instrument [Line Items]
Prepaid fund								139,569		139,569			139,569
Regulation A Filing [Member] | Two Unaffiliated Investors [Member]
Debt Instrument [Line Items]
Accepted stock payment										140,000			140,000
Interest expense								2,700			$ 2,700		5,400	$ 5,400
Accrued Interest								$ 28,507		$ 23,107			$ 28,507
COHEN [Member]
Debt Instrument [Line Items]
Short term bridge loan							$ 500,000
Interest rate							12%
Minimum [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate During Period													9.24%
Maximum [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate During Period													10.90%

Shareholders_ Deficit (Details

Shareholders’ Deficit (Details Narrative) - USD ($)			1 Months Ended	3 Months Ended	6 Months Ended		12 Months Ended
	Nov. 28, 2023	Sep. 01, 2020	Aug. 31, 2020	Dec. 31, 2023	Dec. 31, 2023	Dec. 31, 2022	Jun. 30, 2023
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock forfeited, value				$ 65,075
Common stock, shares authorized				3,000,000,000	3,000,000,000		3,000,000,000
Common stock, par value				$ 0.0001	$ 0.0001		$ 0.0001
Proceeds from issuance of common stock					$ 114,000	$ 659,500
Common stock, shares issued				1,826,705,108	1,826,705,108		1,566,255,108
Common stock, shares outstanding				1,826,705,108	1,826,705,108		1,566,255,108
Regulation A Offering [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock issued new, shares					100,000,000
Proceeds from issuance of common stock					$ 99,000
Subscriptions [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock issued new, shares							160,450,000
BOAPIN [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock issued for purchase of assets, shares		6,700,003
Officers [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares to be issued for compensation, shares					1,958,333
Shares to be issued for compensation, shares					$ 1,854
Series A Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Preferred stock, shares authorized				100,000	100,000		100,000
Preferred stock, par value				$ 0.0001	$ 0.0001		$ 0.0001
Preferred stock, shares issued				688	688		688
Preferred stock, shares outstanding				688	688		688
Series B Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Preferred stock, shares authorized				62,500	62,500		62,500
Preferred stock, par value				$ 0.0001	$ 0.0001		$ 0.0001
Preferred stock, shares issued				9,938	9,938		9,938
Preferred stock, shares outstanding				9,938	9,938		9,938
Series C Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Preferred stock, shares authorized				6,944,445	6,944,445		6,944,445
Preferred stock, par value				$ 0.0001	$ 0.0001		$ 0.0001
Preferred stock, shares issued				5,676,839	5,676,839		6,838,889
Preferred stock, shares outstanding				5,676,839	5,676,839		6,838,889
Series C Preferred Stock [Member] | Hypersoft Ventures [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock issued for purchase of assets, shares			6,700,003
Stock forfeited, shares	1,162,050
Stock forfeited, value	$ 65,075
Series D Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Preferred stock, shares authorized				500,000	500,000		500,000
Preferred stock, par value				$ 0.0001	$ 0.0001		$ 0.0001
Preferred stock, shares issued				425,000	425,000		425,000
Preferred stock, shares outstanding				425,000	425,000		425,000
Series E Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Preferred stock, shares authorized				4,000,000	4,000,000		4,000,000
Preferred stock, par value				$ 0.0001	$ 0.0001		$ 0.0001
Preferred stock, shares issued				4,000,000	4,000,000		4,000,000
Preferred stock, shares outstanding				4,000,000	4,000,000		4,000,000
Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Preferred stock, shares authorized				25,000,000	25,000,000		25,000,000
Preferred stock, par value				$ 0.0001	$ 0.0001		$ 0.0001

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	Dec. 31, 2023	Jun. 30, 2023
Related Party Transaction [Line Items]
Total loans from related parties, net	$ 801,974	$ 799,132
Subsidiary [Member]
Related Party Transaction [Line Items]
Total loans from related parties, net	177,320	177,320
Accrued Salaries Bonus Fees [Member]
Related Party Transaction [Line Items]
Total loans from related parties, net	$ 624,654	$ 621,812

Related Party Transactions (D_2

Related Party Transactions (Details Narrative) - USD ($)			1 Months Ended	3 Months Ended		6 Months Ended
	Nov. 28, 2023	Nov. 03, 2023	Aug. 31, 2020	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022	Jun. 30, 2023
Related Party Transaction [Line Items]
Gain on extinguishment of debt				$ 239,834	$ 0	$ 637,334	$ 0
Notes payable				158,333		158,333		$ 158,333
Peter Pizzino [Member]
Related Party Transaction [Line Items]
Notes payable				279,940		279,940		0
Debt face amount		$ 279,940
Proceeds from loan		$ 279,940
Interest rate		3%
Maturity date		Oct. 07, 2024
Hypersoft Ventures [Member]
Related Party Transaction [Line Items]
Payments to Acquire Productive Assets			$ 800,200
Note issued for purchase of assets			$ 425,000
Debt forgiven	$ 170,000
Interest forgiven	69,834
Gain on extinguishment of debt	$ 239,834
Notes payable				0		0		170,000
Interest expense				0	$ 3,428	0	$ 6,856
Interest payable				$ 0		$ 0		$ 63,015
Hypersoft Ventures [Member] | Series C Preferred Stock [Member]
Related Party Transaction [Line Items]
Stock issued for purchase of assets, shares			6,700,003
Stock issued for purchase of assets, value			$ 375,200

Commitments and contingencies (

Commitments and contingencies (Details Narrative) - USD ($)	Jul. 21, 2023	Dec. 31, 2023
Benza Pharma [Member]
Loss Contingencies [Line Items]
Litigation Settlement, Expense	$ 345,000
Payment of litigation settlement	145,000
Litigation settlement payable	200,000
GRQ Consultants [Member]
Loss Contingencies [Line Items]
Litigation Settlement, Expense	80,000
Payment of litigation settlement	$ 10,000
MCA Cure [Member]
Loss Contingencies [Line Items]
Litigation receivable		$ 148,875

Office_Warehouse lease (Details

Office/Warehouse lease (Details - Rent expense) - USD ($)	6 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Officewarehouse Lease
Rent Expenses	$ 8,160	$ 12,190

Office_Warehouse lease (Detai_2

Office/Warehouse lease (Details - Future lease payments)	Dec. 31, 2023 USD ($)
Officewarehouse Lease
2024	$ 8,160
2025	16,670
July & August 2025	2,790
Total future minimum lease payments	27,620
Less imputed interest	(1,949)
Total present value of future minimum lease payments	$ 25,671

Office_Warehouse lease (Detai_3

Office/Warehouse lease (Details - Lease information) - USD ($)	Dec. 31, 2023	Jun. 30, 2023
Officewarehouse Lease
Operating lease right-of-use assets	$ 25,250	$ 32,157
Accrued lease liability	14,856
Long-term lease liability	10,815	$ 18,468
Operating lease liability	$ 25,671
Weighted Average Remaining Lease Term	1 year 8 months 1 day
Weighted Average Discount Rate	8.44%

Office_Warehouse lease (Detai_4

Office/Warehouse lease (Details Narrative) - USD ($)	Dec. 31, 2023	Jun. 30, 2023
Right of use asset	$ 25,250	$ 32,157
New Lease Agreement [Member]
Right of use asset	$ 43,058
Minimum [Member]
Lease term	3 years
Maximum [Member]
Lease term	5 years

Other income - settlement (Deta

Other income - settlement (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022	Feb. 28, 2022
Other Income and Expenses [Abstract]
Attorney costs					$ 105,125
Settlement income	$ 0	$ 0	$ 0	$ 19,500